Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072159 · ClinicalTrials.gov registry record · NA
Community Pharmacists Vaccinate Against Cancer
A NA study of Human Papillomavirus Vaccines, sponsored by Arizona State University.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT04072159: Completed NA study of Human Papillomavirus Vaccines, sponsored by Arizona State University.
NCT04072159 is a NA study of Human Papillomavirus Vaccines that has completed, run by Arizona State University. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04072159, a NA study of Human Papillomavirus Vaccines, has completed, sponsored by Arizona State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Latino and African American populations have a higher rate of human papillomavirus (HPV) vaccine initiation; however, they have a significantly less likelihood of completing the vaccine series. Pharmacists are licensed to vaccinate against the HPV virus. However, they are less likely to administer the vaccine. Although past research has recommended incorporating pharmacists to increase adolescent vaccination, no intervention studies, to our knowledge, have tested a healthcare delivery model that incorporates pharmacists to complete the HPV vaccine series. The aims of this pilot randomized controlled trial are to 1) determine the preliminary efficacy of an intervention to increase HPV vaccine series completion with the community pharmacist vs. with the primary care provider among racially/ethnically diverse participants, and 2) assess perceived intervention feasibility and acceptability of the intervention among intervention participants and primary care clinic staff.
Primary Outcome
Whether child completed HPV vaccine series with pharmacist (self-report on post-test and patient medical record)
Conditions Studied
Interventions
- BEHAVIORAL Community Pharmacists Vaccinating Against Cancer
Study Locations (1)
Arizona
- Adelante Healthcare Mesa - Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-02-01 |
| Phase | NA |
What the finished NCT04072159 record still lists
NCT04072159 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Human Papillomavirus Vaccines appearing as the primary indexed condition, and to 1 intervention - of which Community Pharmacists Vaccinating Against Cancer is the first listed.
NCT04072159 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT04072159 about?
NCT04072159 is a clinical study titled "Community Pharmacists Vaccinate Against Cancer". Latino and African American populations have a higher rate of human papillomavirus (HPV) vaccine initiation; however, they have a significantly less likelihood of completing the vaccine series. Pharmacists are licensed to vaccinate against the HPV virus. However, they are less likely to administer t...
What is the current status of trial NCT04072159?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2019-04-01. Estimated completion is 2021-02-01.
What conditions does trial NCT04072159 study?
This clinical trial studies the following conditions: Human Papillomavirus Vaccines.
What interventions are being tested in trial NCT04072159?
The interventions under investigation include: Community Pharmacists Vaccinating Against Cancer (BEHAVIORAL).
Who is sponsoring clinical trial NCT04072159?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04072159 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04072159's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI